Chemistry Reference
In-Depth Information
[13] T.I. Opera, A.M. Davies, S.J. Teague and P.D. Leeson, Is there a difference between leads and
drugs? A historical perspective.
J. Chem. Inf. Comput. Sci
.,
41
, 1308-1315 (2001).
[14] J.R. Proudfoot, Drugs, leads, and drug-likeness: an analysis of some recently launched drugs,
Bioorg. Med. Chem. Lett
.,
12
, 1647-1650 (2002).
[15] P.J. Hajduk and J. Greer,Adecade of fragment-based drug design: strategic advances and lessons
learned,
Nat. Rev. Drug Discov
.,
6
, 211-219 (2007).
[16] G. Harper, S.D. Pickett and D.V.S. Green, Design of a compound screening collection for use
in high throughput screening,
Comb. Chem. High Throughput Screen
.,
7
, 63-70 (2004).
[17] M.M. Olah, C.G. Bologa and T.I. Oprea, Strategies for compound selection,
Curr
.
Drug Discov.
Technol
.,
1
, 211-220 (2004).
[18] J.J. Irwin, How good is your screening library?,
Curr. Opin. Chem. Biol
.,
10
, 352-356 (2006).
[19] R.E. Hubbard, I. Chen and B. Davis, Informatics and modelling challenges in fragment-based
drug discovery,
Curr. Opin. Drug Discov. Dev
.,
10
, 289-297 (2007).
[20] A.A. Shelat and R.K. Guy, Scaffold composition and biological relevance of screening libraries,
Nat. Chem. Biol
.,
3
, 442-446 (2007).
[21] U. Schopfer, C. Engeloch, J. Stanek, M. Girod, A. Schuffenhauer, E. Jacoby and P. Acklin, The
Novartis compound archive - from concept to reality,
Comb. Chem. High Throughput Screen
.,
8
, 513-519 (2005).
[22] D.A. Erlanson, R.S. Mcdowell and T O'brien, Fragment-based drug discovery.
J. Med. Chem
.
47
, 3463-3482 (2004).
[23] S. Bartoli, C.I. Fincham and D. Fattori, Fragment-based drug design: combining philosophy
with technology,
Curr. Opin. Drug Discov. Dev
.,
10
, 422-429 (2007).
[24] J. Barker, S. Courtenay, T. Hesterkamp, D. Ullmann and M. Whittaker, Fragment screening by
biochemical assay,
Expert Opin. Drug Discov
.,
1
, 225-236 (2006).
[25] D. A. Erlanson, M.D. Ballinger and J.A. Wells, Tethering, in
Fragment-based Approaches in
Drug Discovery
(ed. W. Jahnke and D.A. Erlanson),
Methods and Principles in Medicinal
Chemistry
, Vol. 34, Wiley-VCH Verlag GmbH, Weinheim, pp. 285-310 (2006).
[26] J. Blaney, V. Nienaber and S.K. Burley, Fragment-based lead discovery and opitization using
X-ray crystallography, computational chemistry, and high-throughput organic synthesis, in
Fragment-based Approaches in Drug Discovery
(ed. W. Jahnke and D.A. Erlanson),
Meth-
ods and Principles in Medicinal Chemistry
, Vol. 34, Wiley-VCH Verlag GmbH, Weinheim,
pp. 215-248 (2006).
[27] M.M. Hann and T.I. Oprea, Pursuing the leadlikeness concept in pharmaceutical research,
Curr.
Opin. Chem. Biol.
,
8
, 255-263 (2004).
[28] N. Baurin, F. Aboul-Ela, X. Barril, B. Davis, M. Drysdale, B. Dymock, H. Finch, C. Fromont,
C. Richardson, H. Simonite and R.E. Hubbard, Design and characterization of libraries of
molecular fragments for use in NMR screening against protein targets,
J. Chem. Inf. Comput.
Sci.
,
44
, 2157-2166 (2004).
[29] M. Snarey, N.K. Terrett, P. Willett and D.J. Wilton, Comparison of algorithms for dissimilarity-
based compound selection,
J. Mol. Graph. Model
.,
15
, 372-385 (1997).
[30] A. Schuffenhauer, N. Brown, P. Selzer, P. Ertl and E. Jacoby, Relationships between molecular
complexity, biological activity, and structural diversity,
J. Chem. Inf. Model
.,
46
, 525-535
(2006).
[31] H.J. Boehm,M. Boehringer, D. Bur, H. Gmuender,W. Huber,W. Klaus, D. Kostrewa, H. Kuehne,
T. Luebbers, N. Meunier-Keller and F. Mueller, Novel inhibitors of DNA gyrase: 3D struc-
ture based biased needle screening, hit validation by biophysical methods, and 3D guided
optimization. A promising alternative to random screening,
J. Med. Chem
.,
43
, 2664-2674
(2000).
[32] M.J. Hartshorn, C.W. Murray, A. Cleasby, M. Frederickson, I.J. Tickle and H. Jhoti, Fragment-
based lead discovery using X-ray crystallography,
J. Med. Chem
.,
48
, 403-413 (2005).
